Tissue Therapies Limited
(ASX:TIS) CEO Steven Mercer presents at ASX Spotlight London about the biomedical technology company’s operations.
The company is developing a product targeted on the treatment of chronic wounds, especially those caused by potentially fatal Diabetic and Venous ulcers.
The VitroGro product emulates the body's natural proteins that stimulate new skin cells and the healing of chronic wounds.
